Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

0.00%

$1.75 viralytics limited

I seriously doubt a low ball offer would last long. The other...

First 43 Last

Share
Profile

Follow
LongNow

1,365 Posts.

11/11/15

07:11

Post #: 16366578
Share

Originally posted by kmsmith ↑

Agree with you totally Bripoz. In the year or so before the latest announcements there was some spectacular news. First $27m share issue. Added such needed cornerstone investors. Meant no concerns about whether we could raise funds for a year. And no more 15% dilutions on new share issues regularly.

Then of course phase 2 results similar to Tvec. Achieved required results by half way.

Only on mobile but from memory increased mkt cap from maybe $40/50 m to around $$100. Considering what had been achieved that was not in my high range of expectations.

N
At this stage we had a drug that had pretty formidable results and money in the bank. Just no obvious interest from drug Co's. Check out announcements and articles of the time and I think Merck and Keytruda will have been mentioned in most.

Now we have an offer to do a trial with Keytruda and the market cap is I believe up 16%. Around $20m and falling??? Vla intended to run such trials but now the costs have been split. Surely this alone have saved the company and increased its value by almost $20m.

The way I see it there is no added valuation for having interest shown by owner of one of big Pd 1 drugs

Mont I hope you right about valuation not being dependent on current share price. Not 100% sure though. If results continue to go as we as they have until now and as preclinical trials suggest they may, if MC remains around $100 the re would be great incentive for Merck to make a low offer and buy the entire Co.

Only good news is the aforementioned cornerstone investors. Hopefully they would not agree.

Anyway it is how it is but I for one am bewildered - not for the first time at current share price.
All the best
Kms

Expand

I seriously doubt a low ball offer would last long. The other pharmas would be happy to cut Merck's lunch.

VLA Price at posting: 63.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas